



**HAL**  
open science

# Validation of Alzheimer's disease CSF and Plasma Biological Markers The Multi-Center Reliability Study of the Pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)

Katharina Buerger, Giovanni B. Frisoni, Olga Uspenskaya, Michael Ewers, Henrik Zetterberg, Cristina Geroldi, Giuliano Binetti, Peter Johannsen, Paolo Maria Rossini, Lars-Olof Wahlund, et al.

## ► To cite this version:

Katharina Buerger, Giovanni B. Frisoni, Olga Uspenskaya, Michael Ewers, Henrik Zetterberg, et al.. Validation of Alzheimer's disease CSF and Plasma Biological Markers The Multi-Center Reliability Study of the Pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). *Experimental Gerontology*, 2009, 44 (9), pp.579. 10.1016/j.exger.2009.06.003 . hal-00510618

**HAL Id: hal-00510618**

**<https://hal.science/hal-00510618>**

Submitted on 20 Aug 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

Validation of Alzheimer's disease CSF and Plasma Biological Markers The Multi-Center Reliability Study of the Pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)

Katharina Buerger, Giovanni Frisoni, Olga Uspenskaya, Michael Ewers, Henrik Zetterberg, Cristina Geroldi, Giuliano Binetti, Peter Johannsen, Paolo Maria Rossini, Lars-Olof Wahlund, Bruno Vellas, Kaj Blennow, Harald Hampel


PII: S0531-5565(09)00116-8  
DOI: [10.1016/j.exger.2009.06.003](https://doi.org/10.1016/j.exger.2009.06.003)  
Reference: EXG 8617

To appear in: *Experimental Gerontology*

Received Date: 6 April 2009  
Revised Date: 9 June 2009  
Accepted Date: 10 June 2009

Please cite this article as: Buerger, K., Frisoni, G., Uspenskaya, O., Ewers, M., Zetterberg, H., Geroldi, C., Binetti, G., Johannsen, P., Rossini, P.M., Wahlund, L-O., Vellas, B., Blennow, K., Hampel, H., Validation of Alzheimer's disease CSF and Plasma Biological Markers The Multi-Center Reliability Study of the Pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI), *Experimental Gerontology* (2009), doi: [10.1016/j.exger.2009.06.003](https://doi.org/10.1016/j.exger.2009.06.003)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Validation of Alzheimer's disease CSF and Plasma Biological Markers****The Multi-Center Reliability Study****of the Pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)**

Katharina Buerger<sup>1\*</sup>, Giovanni Frisoni<sup>2</sup>, Olga Uspenskaya<sup>1,3</sup>, Michael Ewers<sup>1,4</sup>,

Henrik Zetterberg<sup>5</sup>, Cristina Geroldi<sup>2</sup>, Giuliano Binetti<sup>2</sup>, Peter Johannsen<sup>6</sup>, Paolo Maria Rossini<sup>7</sup>,

Lars-Olof Wahlund<sup>8</sup>, Bruno Vellas<sup>9</sup>, Kaj Blennow<sup>5</sup>, and Harald Hampel<sup>1,4\*</sup>

<sup>1</sup>Department of Psychiatry & Alzheimer Memorial Center and Geriatric Psychiatry Branch, Ludwig-Maximilian University Munich, Nussbaumstrasse 7, 80336 Munich, Germany (Phone: +49-89-5160 5877, Fax +49-89-5160 5865, E-mail: [katharina.buerger@med.uni-muenchen.de](mailto:katharina.buerger@med.uni-muenchen.de); [harald.hampel@med.uni-muenchen.de](mailto:harald.hampel@med.uni-muenchen.de))

<sup>2</sup>IRCCS Centro San Giovanni di Dio, Brescia, Italy

<sup>3</sup>Department of Neurology, I.M. Sechenov Moscow Medical Academy, Moscow, Russia

<sup>4</sup>Discipline of Psychiatry, School of Medicine & Trinity College, Trinity College Institute of Neuroscience (TCIN), Laboratory of Neuroimaging & Biomarker Research, University of Dublin, The Adelaide and Meath Hospital Incorporating the National Children's Hospital (AMiNCH), Dublin, Ireland (Phone: +353 1 896 3706; Fax: +353 1-896 1313; E-mail: [harald.hampel@tcd.ie](mailto:harald.hampel@tcd.ie), [harald.hampel@med.uni-muenchen.de](mailto:harald.hampel@med.uni-muenchen.de), [michael.ewers@tcd.ie](mailto:michael.ewers@tcd.ie))

<sup>5</sup>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Göteborg University, Mölndal, Sweden

<sup>6</sup>Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark

<sup>7</sup>Clinical Neurology, University 'Campus Biomedico', Rome, Italy and Casa di Cura S. Raffaele Cassino & IRCCS S. Raffaele Pisana, Rome, Italy

<sup>8</sup>Karolinska Institute, Department of Clinical Neuroscience and Family Medicine, Huddinge, University Hospital, Huddinge, Sweden

<sup>9</sup>Department of Internal Medicine and Gerontology, Alzheimer Disease Centre, CHU Purpan-Casselardit, Toulouse, France

**Running title:** Pilot E-ADNI CSF & Plasma study

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Manuscript requirements:**

Title	175 characters
Running title	31 characters
Abstract	200 words
Text	3614 words
References	19
Tables	4
Figures	1

**Corresponding Author:**

Katharina Buerger, M.D., Dementia Research Section and Memory Clinic, Alzheimer Memorial Centre and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany, (Phone: +49 89 5160 5877, Fax: +49 89 5160 5865, e-mail: [katharina.buerger@med.uni-muenchen.de](mailto:katharina.buerger@med.uni-muenchen.de))

This paper was presented in part by the senior author (H.H.) at the Alzheimer's Association Research Roundtable Meeting as an invited presentation in Washington, D.C., USA, November 14<sup>th</sup>, 2007.

**Abstract**

1 *Background* Alzheimer's Disease Neuroimaging Initiatives ("ADNI") aim to validate neuroimaging  
2 and biochemical markers of Alzheimer's disease (AD). Data of the pilot European ADNI (E-ADNI)  
3 biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are  
4 reported.  
5  
6  
7  
8

9  
10 *Methods* Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild  
11 cognitive impairment (MCI) and AD). We measured CSF  $\beta$ -amyloid 42 (CSF A $\beta$ 42), total tau-  
12 protein (t-tau), phosphorylated tau-proteins (P-tau181, P-tau231), plasma  $\beta$ -amyloid 40 and 42  
13 (A $\beta$ 40 / A $\beta$ 42). Immediate fresh shipment was compared to freezing and later shipment on dry ice.  
14  
15  
16  
17  
18

19  
20 *Results* CSF T-tau (fresh samples) was increased in AD versus controls ( $p=0.049$ ), CSF A $\beta$ 42  
21 (frozen samples) was decreased in MCI and AD ( $p=0.02$ ), as well as plasma A $\beta$ 40 (fresh and frozen  
22 samples) in AD ( $p=0.049$  and  $p=0.016$ ). Pooled values of neurochemical parameters and ratios  
23 thereof were different between centres ( $p<0.005$ ). Analysis of frozen samples yielded higher  
24 diagnostic accuracy than immediate fresh shipment with 100% (fresh: 100%) correctly classified in  
25 control subjects, 100% (78%) in MCI, 91% (91%) in AD.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 *Conclusion* The use of frozen rather than fresh samples renders higher diagnostic accuracy within a  
36 multicenter context. We confirmed the feasibility of a multi-centre AD biomarker programme for  
37 future clinical trials.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 **Key words:** Alzheimer's disease (AD), mild cognitive impairment (MCI), Alzheimer's Disease  
56 Neuroimaging Initiative (ADNI), biological marker, validation.  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Abbreviations:**

1 AD = Alzheimer's disease

2  
3 MCI = mild cognitive impairment

4  
5  
6 ADNI = Alzheimer's Disease Neuroimaging Initiative

7  
8  
9 E-ADNI = European ADNI

10  
11  
12 EADC = European Alzheimer's Disease Consortium

13  
14  
15 neuGRID = FP7 "A Grid-Based e-Infrastructure for Data Archiving/Communication and  
16  
17 Computationally Intensive Applications in the Medical Sciences"

18  
19  
20 FDG PET = fluorodeoxyglucose positron emission tomography

21  
22  
23 CSF = cerebrospinal fluid

24  
25  
26 ANOVA = analysis of variance

27  
28  
29 LSD = least significant difference

30  
31  
32 SD = standard deviation

33  
34  
35 ELISA = enzyme-linked immunosorbent assay

36  
37  
38 NINDS-AIREN = National Institute for Neurological Disorders and Stroke-Association  
39  
40 Internationale pour la Recherche et l'Enseignement en Neurosciences

41  
42  
43 MMSE = Mini-Mental State Examination

44  
45  
46 ADAS-Cog = Alzheimer's Disease Assessment Scale-Cognitive Subscale

47  
48  
49 DRadas = delayed recall test from the ADAS-Cog

50  
51  
52 DNA = deoxyribonucleic acid

53  
54  
55 PI = principal investigator

56  
57  
58 A $\beta$ 40 =  $\beta$ -amyloid 40

59  
60  
61 A $\beta$ 42 =  $\beta$ -amyloid 42

62  
63  
64  
65

t-tau = total tau-protein

P-tau181 = phosphorylated tau-protein 181

P-tau231 = phosphorylated tau-protein 231

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

ACCEPTED MANUSCRIPT

## 1. Introduction

1 The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to collect core feasible  
2 neuroimaging and biochemical marker data in the US and Canada to validate these markers for use  
3 in AD diagnostic and treatment trials. A major goal of the pilot European-ADNI (E-ADNI)  
4 programme of the European Alzheimer's Disease Consortium (EADC) is to test the ability of  
5 European expert centres to implement the data acquisition procedures of the large-scale NIH funded  
6 US-ADNI and use them on the US-ADNI clinical target groups (healthy aging, MCI subjects, and  
7 patients with Alzheimer's disease) (Frisoni et al., 2008).  
8  
9

10 In the US, the ADNI has recruited large groups of Alzheimer's and MCI subjects and normal  
11 controls in about 60 clinical and research centres and collected imaging, clinical, and biological data  
12 in a standardized and centralized fashion that allows for pooled cross-sectional and prospective  
13 analyses (Mueller et al., 2005).  
14  
15

16 Similarly in Europe, 50 clinical and research centres of the EADC are currently running Europe  
17 wide clinical trials which collect clinical, imaging, and biological information in a standardized  
18 fashion while harmonization and centralized collection are cared for by external agencies. Further  
19 evidence of coordinated multisite AD studies in Europe include the recently completed six-year  
20 large-scale German Competence Network, the Swedish network on Alzheimer's Disease, and a  
21 multicentre fluorodeoxyglucose positron emission tomography (FDG PET) imaging study funded  
22 by the EC (Herholz, 2003; Herholz et al., 2002).  
23  
24

25 The aim of this pilot project is to demonstrate that the core ADNI methodology, i.e. standardized  
26 and centralized collection of magnetic resonance (MR) imaging, clinical data, blood, and CSF  
27 samples can be adopted by European expert academic Alzheimer's centres to collect reliable,  
28 accurate and robust data. Few test sites and subjects were involved to collect single time point data.  
29  
30 Once collected by the participating centres, data and specimens were sent to central repositories  
31 through conventional means (CD for images; e-mail attachments for the clinical data; express  
32 courier for the biological samples). The whole infrastructure for centralized data collection is under  
33 development (FP7 "neuGRID: a Grid-Based e-Infrastructure for Data Archiving/Communication  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



and Computationally Intensive Applications in the Medical Sciences”, [www.neuGRID.eu](http://www.neuGRID.eu)). Thus, neuGRID and the present pilot E-ADNI are providing information whose integration will facilitate the implementation of a future larger study within the EC.

In the current article, we present the results of the E-ADNI biological marker programme’s CSF and plasma studies for the first time, obtained within the "Pilot E-ADNI" study (coordinated by the PI’s Harald Hampel, Germany/Ireland and Kaj Blennow, Sweden). We place a special emphasis on the assessment of the core feasible biochemical marker candidates (as defined by the NIA Biological Marker Working Group (Frank et al., 2003)) CSF A $\beta$ 42, t-tau and P-tau181 and P-tau 231 and of plasma A $\beta$ 40 and A $\beta$ 42. Alterations of these biomarkers in AD and MCI subjects compared to healthy elderly controls have largely been shown (Blennow and Hampel, 2003; Hampel et al., 2008) and they have been suggested core biological markers for AD (Frank et al., 2003). Therefore, these markers were investigated in the current pilot feasibility study.

## 2. Materials and Methods

### 2.1 Centres

Centres for the E-ADNI study were selected mostly from the EADC based on scientific expertise, demonstrated activity within the Consortium, and geographic representativeness. CSF and plasma samples for neurochemical analysis were obtained from the following E-ADNI centres: Dept. of Psychiatry, Ludwig-Maximilian University, Munich, Germany; IRCCS Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy; Huddinge Hospital, Huddinge, Sweden; MDRU, Rigshospitalet, Copenhagen, Denmark; Ospedale S Giovanni Calibita, Isola Tiberina, Roma; Centre Hospitalier Université de Toulouse, France (provided plasma samples only). Responsibility for clinical issues including adaptation of the US ADNI case report form and collection of the clinical variables was in Toulouse (Centre Hospitalier Université de Toulouse, France); the centre for imaging issues including installation of ADNI sequences, scanner qualification, image quality control, image collection, and analysis was located in Amsterdam (VU Medical Centre, Amsterdam, The Netherlands); CSF issues including adaptation of the US ADNI CSF collection protocol, centralized collection of samples, and assaying were handled in Munich (Dept. of Psychiatry, Ludwig-

Maximilian University, Munich, Germany); plasma issues including adaptation of the US ADNI plasma collection protocol, centralized collection of samples, and assaying were handled in Gothenburg (Dept. of Clinical Neuroscience, University of Gothenburg, Sweden). The centre in Brescia (IRCCS Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy) was responsible for the overall project management, training of personnel in enrolment sites, monitoring of data, image, and sample collection, as well as for reporting.

## 2.2 Patients

Each centre was asked to enrol 3 consecutive newly diagnosed patients with Alzheimer's disease, 3 patients with MCI (**single and multiple domain amnesic MCI (Petersen and Touchon, 2005)**), and 3 normal age-matched controls. Controls were older patients undergoing prostate or hip surgery with spinal anaesthesia (Brescia and Rome), true volunteers, usually patients' spouses (Stockholm, Toulouse and Copenhagen), and persons with memory complaints with normal results in clinical and instrumental exams diagnosed as functional complaints (Munich). The subjects were enrolled between January 1<sup>st</sup> to March 31<sup>st</sup> 2007. All subjects underwent MR scan and lumbar puncture (LP) under routine clinical conditions and the same data, image, and sample collection procedures. Patients and controls were explained the aim of the project, and gave informed consent. The study was reviewed and approved first by the Ethics Committee of the coordinating site (CEIOC – Comitato Etico delle Istituzioni Ospedaliere Cattoliche), then by Ethics Committees of all other sites. None of the subjects fulfilled one or more of the National Institute for Neurological Disorders and Stroke – Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia.

## 2.3 Clinical and neuropsychological data collection

The clinical core module aimed to adapt the ADNI clinical data collection form to the E-ADNI centres. For the purely clinical data (sociodemographics, disability, behaviour, comorbidity, etc.), translation was performed into local languages – the usual procedure of translation and back translation was applied for some scales that were unavailable in local versions.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Adaptation of neuropsychological tests tapping language functions, memory, and attention that use a linguistic strategy was a most sensitive issue in the study. The greatest problem for European multicentre studies on cognition is the equivalence of language-based tests in the different idioms and, consequently, normative data. Local validated versions of the neuropsychological tests were used in all E-ADNI sites. The Rey Auditory Verbal Learning Test was not included in the pilot E-ADNI battery in order to avoid interference with word list recall test of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) as all cognitive tests were done in a single assessment. The Digit Span Forward and Backward were not included for time constraints. The North American Reading Test was not done because correspondent versions in local idioms were unavailable.

#### 2.4 MR-imaging

MR imaging was a part of the pilot E-ADNI study and data will be provided in a separate manuscript.

#### 2.5 Blood, plasma, and CSF

Blood, plasma, and CSF collection and storage procedures were adapted from the ADNI-protocol, agreed between the biological PI centres (Munich and Gothenburg), and transferred to E-ADNI centres in order to create blood, plasma, and CSF repositories.

Blood and CSF were drawn and pre-processed at each of the centres according to an ADNI modified protocol, and sent to the biological principal investigator (PI) centres (Munich for CSF and Gothenburg for plasma). Serum analyses were not included in the pilot study, because if plasma analyses work well, so will serum analyses.

Obtained biological fluids were used to evaluate the levels of following parameters: A $\beta$ 42, t-tau, and phosphorylated tau-protein (P-tau181 and P-tau 231) in CSF; A $\beta$ 42 and A $\beta$ 40 in plasma; DNA was not shipped and analyses were performed for APOE genotyping in the participating centres.

**Data on patient recruitment, data collection, and clinical, neuropsychological, and imaging features have been described elsewhere in greater detail (Frisoni et al., 2008); the English**

version of the Case Report Form used in the present study can be downloaded from [http://www.centroAlzheimer.it/E-ADNI\\_project.htm](http://www.centroAlzheimer.it/E-ADNI_project.htm).

Procedures for collection, processing, aliquotation, storage and shipment of samples of biological fluids

All samples were collected in the morning (8-11 am) to avoid diurnal variations.

*Cerebrospinal fluid:* Lumbar punctures were performed with the patient either lying down or sitting. CSF was obtained using a small gauge needle to avoid headache. The first 1 ml (2 ml in case of bleeding at the puncture) of CSF was discarded. Approximate volume of collected CSF was 8 ml (5 ml for the study and 1-3 ml for standard tests). CSF was collected in polypropylene tubes to avoid adsorbance of peptides and proteins to the test tube wall. The obtained sample was immediately sent (<30 min) to the local laboratory, where it was mixed thoroughly by hand and 1-3 ml was taken off for standard tests, i.e. cell count, protein analyses, and others. The CSF sample intended for the study was centrifuged in the original polypropylene tube at 2.000 x g for 10 min. at +4°C, to eliminate cells and other insoluble material. One 1.0 ml aliquot of CSF was immediately sent in an appropriate box at room temperature to the biological PI centre in Munich (Germany) by courier mail. Remaining 4 ml were aliquoted in 8 x 0.5 ml portions, frozen at -80°C, and stored until all patients at the centre were included and samples were sent in one batch. The samples were then sent, on dry ice in an appropriate box to Munich by courier mail.

*Plasma:* Plasma samples were collected by venipuncture in tubes containing EDTA as anticoagulant. After centrifugation, plasma samples were aliquoted in polypropylene tubes and stored at -80°C pending biochemical analyses.

Analysis of samples

All measurements of CSF A $\beta$ 42, CSF t-tau and P-tau181 in CSF were performed in Munich, Germany (biological PI centre). These parameters were measured in duplicates with commercially available enzyme-linked immunosorbent assays (ELISA) (Innotest b-amyloid1-42, Innotest hTAU-Ag, Innogenetics, Innotest PHOSPHO-TAU (181P) Zwjindrecht, Belgium, Art. No. K-1080, Art No. K-1032, and Art No. K-1120). Levels of CSF P-tau231 in CSF were measured using a sandwich ELISA developed by Applied NeuroSolutions, Inc. (Vernon Hills, IL).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Quantification of  $\beta$ -amyloid isoforms in plasma was performed in the biological PI centre in Gothenburg, Sweden, using the high sensitivity INNOTEST A $\beta$ 1-42 ELISA (Innogenetics, Ghent, Belgium), as previously described (Vanderstichele et al., 2000).  $\beta$ -amyloid 40 levels were determined using the hAmyloid  $\beta$ 40 ELISA Highly Sensitive kit (The Genetics Company, Schlieren, Switzerland). This assay employs antibody W02 (epitope 5-8 in the A $\beta$  sequence) for capture and the A $\beta$ 40 end-specific antibody G2-10 for detection (Hansson et al., 2007).

APOE genotyping was performed according to standard procedures by local laboratories of the E-ADNI centres.

### 2.6 Statistical analysis

In order to document differences between the groups and centres clinical, neuropsychological and laboratory variables as well as ratios of “frozen/fresh biomarker” were compared using nonparametric Kruskal-Wallis one-way analysis of variance (ANOVA). The homogeneity of variances was assessed with Levene and Brown-Forsythe tests. The Bonferroni least significant difference (LSD) test was used for post hoc analysis. Discriminant analysis was performed in order to determine which method of sample storage contributes to better classification of patients to diagnostic groups. Spearman’s rank and Pearson correlation coefficients were used to assess the correlations between different biomarkers, as well as between diagnoses and biomarker levels. All data are presented as means  $\pm$  standard deviation (SD). Differences were considered significant at  $p < 0.05$ . Data were analysed using the Statistical Package for Social Sciences (SPSS for Windows, version 15.0, SPSS Inc., 2006).

## 3. Results

### 3.1 Demographics

A total of 49 subjects were recruited with a mean age of  $70.2 \pm 10.6$  (range 42-87) years. In the study participated 26 (53%) male and 23 (47%) female subjects. The distribution of number of patients in the centres is shown in the Figure 1.

Over all centres were recruited 15 (31%) healthy older controls, 17 (35%) subjects with MCI, and 17 (35%) AD-patients. The distribution of number of cases with particular diagnosis in every centre

was rather uniform, although the precise statistical verification is not possible because of small sample sizes (for detailed information see Figure 1).

### 3.2 Cognitive testing

Mean Mini-Mental State Examination (MMSE) score [points] in healthy controls was  $29.0 \pm 0.7$ , in MCI subjects  $27.1 \pm 2.1$ , and in AD-patients  $23.0 \pm 3.3$ . The MMSE score was statistically different in healthy controls versus MCI ( $p=0.027$ ) and AD-patients ( $p<0.0005$ ), as well as in MCI-subjects versus AD-patients ( $p<0.0005$ ).

Mean delayed recall test from the ADAS-Cog (DRadas) score in healthy controls was  $6 \pm 2.4$  points, in MCI subjects  $3 \pm 2.6$  points, in AD-patients  $1 \pm 1.6$  points. The DRadas score in healthy controls significantly differed from that of patients with MCI ( $p=0.002$ ) and AD ( $p<0.0005$ ), and in MCI subjects differed from that of AD patients ( $p=0.028$ ).

### 3.3 Laboratory data

The mean levels of neurochemical parameters measured in CSF and plasma within centres are presented in the Table 1.

There are no statistically significant differences between means of parameters measured in different centres.

We also performed a statistical analysis of differences of overall means of neurochemical parameters depending on diagnosis and without consideration of centres (Table 2).

We found statistically significant differences of CSF t-tau value (fresh samples) in healthy controls versus AD-patients (healthy controls  $<$  AD;  $p=0.049$ ), CSF A $\beta$ 42 value (frozen samples) in healthy controls versus MCI-subjects and AD-patients (healthy controls  $>$  MCI  $>$  AD;  $p=0.02$ ), plasma A $\beta$ 40 (fresh samples) in healthy controls versus AD-patients (healthy controls  $>$  AD;  $p=0.049$ ), and plasma A $\beta$ 40 value (frozen samples) in healthy controls versus AD-patients (healthy controls  $>$  AD;  $p=0.016$ ). Differences of other neurochemical parameters between groups did not reach statistical significance, although their change showed an expected trend, namely the values of CSF t-tau measured in frozen samples and CSF P-tau181 and 231 (fresh and frozen samples) were higher in MCI- and AD-patients than in normal controls, and in AD-patients versus MCI-subjects; the values of CSF A $\beta$ 42 (fresh and frozen samples) were lower in AD-patients than in MCI-patients, as well as

1 plasma A $\beta$ 40 (fresh and frozen samples) were lower in AD patients compared to MCI-patients and  
2 in MCI-patients versus healthy controls. In addition, the values of plasma A $\beta$ 42 (fresh and frozen  
3 samples) were lower in AD and MCI-patients compared to healthy controls and in AD patients than  
4 in MCI-patients.  
5

6  
7 In order to evaluate the influence of sample storage and shipment on the results of tau-proteins and  
8 beta-amyloid measurements, the “fresh / frozen marker” ratios between the centres were calculated  
9 (Table 3).  
10  
11

12 We also performed an analysis of cumulative values of neurochemical parameters with and without  
13 freezing without consideration of centres. We have found no significant differences between  
14 cumulative biomarker values measured in fresh and frozen samples, but strong positive correlations  
15 between biomarker levels in fresh and frozen samples (see Table 4). Discriminant analysis was  
16 performed in order to determine which method of sample storage contributes to better classification  
17 of patients to diagnostic groups. We introduced the demographic (age, gender) and  
18 neuropsychological (MMSE, DRadas) variables together with the biomarker levels measured in  
19 fresh or frozen samples. The use of fresh samples resulted in 100% correctly classified cases in the  
20 healthy controls group, 77.8% in MCI- and 90.9% in AD-group compared to 100% in healthy  
21 controls and MCI-groups, and 90.9% in AD-group when using frozen samples.  
22  
23

24 Positive correlations (Spearman's correlation analysis) between the levels of plasma A $\beta$ 40 (fresh  
25 samples) and plasma A $\beta$ 42 ( $r=0.296$ ,  $p=0.041$  for fresh samples, and  $r=0.285$ ,  $p=0.05$  for frozen  
26 samples); the same is true for the plasma A $\beta$ 40 measured in frozen samples and plasma A $\beta$ 42  
27 values ( $r=0.330$ ,  $p=0.022$  for fresh samples, and  $r=0.382$ ,  $p=0.007$  for frozen samples) were found.  
28  
29 There are no correlations between the levels of fresh or frozen A $\beta$ 40 and 42 measured in plasma  
30 and in CSF.  
31  
32

33 The Spearman's correlation analysis of diagnosis with different neurochemical parameters showed  
34 weak positive correlations of normal cognitive status with the level of CSF A $\beta$ 42 measured in fresh  
35 samples ( $r=0.323$ ,  $p=0.042$ ), level of plasma A $\beta$ 40 measured in frozen samples ( $r=0.287$ ,  
36  $p=0.045$ ), and the level of plasma A $\beta$ 42 measured in frozen ( $r=0.348$ ,  $p=0.015$ ) and in fresh  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

samples ( $r= 0.293$ ,  $p=0.041$ ), as well as weak negative correlation with the level of CSF t-tau measured in fresh samples ( $r= -0.364$ ,  $p=0.018$ ).

### 3.4 Genetic analysis

All patients were assessed for APOE genotype. APOE $\epsilon$ 2 allele in heterozygosity was found in 5 (10.2%) subjects (1 healthy patient, 2 MCI-subjects and 2 AD-patients). APOE $\epsilon$ 3 allele in heterozygosity was found in 23 (46.9%) subjects (8 healthy controls, 9 MCI-subjects, 6 AD-patients), the same allele in homozygosity was found in 21 (42.9%) subjects (7 healthy controls, 7 MCI-subjects, 7 AD-patients). APOE $\epsilon$ 4 allele in heterozygosity was found in 20 (40.8%) subjects (7 healthy controls, 7 MCI-subjects, 6 AD-patients), the same allele in homozygosity was found in 4 (8.2%) subjects (1 MCI-subject and 3 AD-patients). We found no differences between the groups in APOE genotype as well as no correlations between diagnosis and APOE genotype.

## 4. Discussion

**The main finding of the study reported here is that use of frozen rather than fresh samples renders higher diagnostic accuracy within a multicenter context. Moreover, we show that the cooperation between different European centres within international multi-centre MCI and AD studies is feasible.**

Six E-ADNI centres succeeded to recruit normal controls, MCI- and AD-patients for clinical and neuropsychological assessment, as well as to collect and correctly transfer blood and CSF samples to the reference centres. This fact permitted us to perform statistical analysis of differences of overall means of neurochemical parameters depending on diagnosis without consideration of centres. In order to exclude Type I error post hoc analysis was controlled with the help of Bonferroni least significant difference test. We found significant differences of CSF t-tau value (fresh samples) in healthy controls versus AD-patients, of CSF A $\beta$ 42 value (frozen samples) in healthy controls versus MCI-subjects and AD-patients, of plasma A $\beta$ 40 (fresh samples) in healthy controls versus AD-patients, and of plasma A $\beta$ 40 value (frozen samples) in healthy controls versus AD-patients; another evidence of the fact that these significances are not a consequence of randomness is that other neurochemical parameters also showed an expected trend, although the statistical significance was not achieved probably due to small sample sizes.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In order to determine the best way of sample storage and shipment for future studies, we assessed the influence of delayed or immediate freezing on the results of protein measurements and calculated the ratios of fresh / frozen protein levels. We have also performed an analysis of pooled values of neurochemical parameters with and without freezing, again without taking into consideration the centres. We found no significant differences in the pooled values of CSF and plasma biomarkers measured in frozen versus fresh samples. Although, statistically significant differences of some described ratios stipulate in the future the need of unified method of blood and CSF samples storage and transportation, despite the fact of strong positive correlations between pooled values of neurochemical parameters with and without freezing. This statement is confirmed by the results of the discriminant analysis showing that the use of frozen samples for biomarker assessment contributes to better classification of patients to diagnostic groups. We can conclude that the use of frozen samples shipped on the dry ice would be preferable for future multicentre biomarker studies.

The analysis of the pilot E-ADNI study also permitted to find correlations of cognitive status with the levels of CSF A $\beta$ 42, plasma A $\beta$ 40 and 42, and CSF t-tau. This finding is in line with some earlier studies (de Leon et al., 2006; Tapiola et al., 2000), but is not a consistent finding (Buerger et al., 2002a; Hampel et al., 2001) probably due differences in age and dementia severity in the populations studied.

**The main limitation of the present pilot study is the small size of the samples. As a result we have found few statistically significant differences of the neurochemical parameters, although many showed the expected trend. Furthermore, we have found no relationship of neurochemical parameters with APOE genotype and no correlation between diagnosis and APOE genotype, which is probably again due to the small size of samples. While this pilot study was powered for feasibility rather than testing biological hypotheses, future large-scale multi-centre European studies will require much larger sample size.**

The core feasible biomarkers of AD should fulfill the criteria established by the expert consensus conference (1998). The potential marker should reflect a neuropathological characteristic of AD, should be validated in patients with neuropathologically confirmed diagnosis, reach the sensitivity

of at least 85%, and specificity to differentiate AD from age-matched controls and other dementias of at least 75%. Currently, the regulatory authorities, such as FDA and EMEA, recommend validation of core feasible biomarkers of AD as primary end-points in upcoming phase II and III treatment trials of potential disease-modifying therapeutics (Hampel et al., 2008). Several CSF biomarkers, such as t-tau, p-tau and A $\beta$ 42, were already studied or are being evaluated within controlled multicentre phase IIb studies (Buerger et al., 2002b; Ewers et al., 2007; Hampel et al., 2004), other new potential biomarkers (BACE1 and isoprostanes) are undergoing phase I or IIa studies (Zhong et al., 2007). The thorough validation of core feasible biomarkers, however, can be achieved only as a result of a collaboration between leading academic centres. The results of the pilot E-ADNI study prove the feasibility of the multicentre biomarker measurement in the future large-scale EU studies.

The pilot E-ADNI study was aimed to act as a springboard to prepare a more extensive longitudinal study in the EU as a companion or complement to the US-ADNI. The more extensive longitudinal EU study also benefits from another effort – the FP7-funded neuGRID study, aimed to develop the infrastructure for clinical data and image collection of a large E-ADNI study. Thus, neuGRID together with the pilot (aimed at testing the feasibility of data collection) should provide a formidable thrust for the preparation of the larger EU study.

**Disclosure statement for authors**

1 The authors have no conflicts of interest to disclose. The industry sponsors had no role in the  
2 analysis or interpretation of these data nor in the content of the paper. Appropriate approval  
3  
4 procedures were used concerning human subjects.  
5  
6  
7  
8

**Acknowledgements**

9  
10  
11 This study has been funded by a research grant of the Alzheimer's Association, Chicago, Ill., USA:  
12  
13 "*The European Alzheimer's Disease Neuroimaging Initiative*": a pilot study of the European  
14  
15 Alzheimer's Disease Consortium – Pilot E-ADNI", Principal Investigator Giovanni B Frisoni, Italy,  
16  
17  
18 Principal Investigators of the Pilot E-ADNI biological marker programme: Harald Hampel,  
19  
20  
21 Ireland/Germany and Kaj Blennow, Sweden.  
22  
23  
24

25 The authors thank Yvonne Hoessler for excellent technical assistance.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

- 1  
2 1998. Consensus report of the Working Group on: "Molecular and Biochemical Markers of  
3  
4 Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's  
5  
6 Association and the National Institute on Aging Working Group. *Neurobiol Aging* 19, 109-  
7  
8 116.  
9  
10  
11  
12 Blennow, K., Hampel, H., 2003. CSF markers for incipient Alzheimer's disease. *Lancet Neurol* 2,  
13  
14 605-613.  
15  
16  
17 Buerger, K., Teipel, S.J., Zinkowski, R., Blennow, K., Arai, H., Engel, R., Hofman-Kiefer, K.,  
18  
19 McCulloch, B.S., Ptok, U., Heun, R., Andreasen, N., DeBernardis, J., Kerkman, D., Moeller,  
20  
21 H.-J., Davies, P., Hampel, H., 2002a. CSF tau protein phosphorylated at threonine 231  
22  
23 correlates with cognitive decline in MCI subjects. *Neurology* 59, 627-630.  
24  
25  
26 Buerger, K., Zinkowski, R., Teipel, S.J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N.,  
27  
28 Hofman-Kiefer, K., DeBernardis, J., Kerkman, D., McCulloch, B.S., Kohnken, R., Padberg,  
29  
30 F., Pirttila, T., Schapiro, M.B., Rapoport, S.I., Moeller, H.-J., Davies, P., Hampel, H., 2002b.  
31  
32 Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein  
33  
34 phosphorylated at threonine 231. *Arch Neurol* 59, 1267-1272.  
35  
36  
37  
38 de Leon, M.J., DeSanti, S., Zinkowski, R., Mehta, P.D., Pratico, D., Segal, S., Rusinek, H., Li, J.,  
39  
40 Tsui, W., Saint Louis, L.A., Clark, C.M., Tarshish, C., Li, Y., Lair, L., Javier, E., Rich, K.,  
41  
42 Lesbre, P., Mosconi, L., Reisberg, B., Sadowski, M., DeBernadis, J.F., Kerkman, D.J.,  
43  
44 Hampel, H., Wahlund, L.O., Davies, P., 2006. Longitudinal CSF and MRI biomarkers  
45  
46 improve the diagnosis of mild cognitive impairment. *Neurobiology of aging* 27, 394-401.  
47  
48  
49  
50  
51 Ewers, M., Buerger, K., Teipel, S.J., Scheltens, P., Schroeder, J., Zinkowski, R.P., Bouwman, F.H.,  
52  
53 Schoenknecht, P., Schoonenboom, N.S., Andreasen, N., Wallin, A., DeBernardis, J.F.,  
54  
55 Kerkman, D.J., Heindl, B., Blennow, K., Hampel, H., 2007. Multicenter assessment of CSF-  
56  
57 phosphorylated tau for the prediction of conversion of MCI. *Neurology* 69, 2205-2212.  
58  
59  
60  
61 Frank, R.A., Galasko, D., Hampel, H., Hardy, J., de Leon, M.J., Mehta, P.D., Rogers, J., Siemers,  
62  
63 E., Trojanowski, J.Q., 2003. Biological markers for therapeutic trials in Alzheimer's disease.  
64  
65

Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. *Neurobiology of aging* 24, 521-536.

1  
2 Frisoni, G.B., Henneman, W.J., Weiner, M.W., Scheltens, P., Vellas, B., Reynish, E., Hudecova, J.,  
3  
4 Hampel, H., Buerger, K., Blennow, K., Waldemar, G., Johannsen, P., Wahlund, L.O., Zito, G.,  
5  
6 Rossini, P.M., Winblad, B., Barkhof, F., 2008. The pilot European Alzheimer's Disease  
7  
8 Neuroimaging Initiative of the European Alzheimer's Disease Consortium. *Alzheimers*  
9  
10 *Dement* 4, 255-264.  
11

12  
13  
14 Hampel, H., Buerger, K., Kohnken, R., Teipel, S.J., Zinkowski, R., Moeller, H.J., Rapoport, S.I.,  
15  
16 Davies, P., 2001. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau  
17  
18 protein phosphorylated at threonine 231. *Ann Neurol* 49, 545-546.  
19

20  
21  
22 Hampel, H., Buerger, K., Teipel, S.J., Bokde, A.L., Zetterberg, H., Blennow, K., 2008. Core  
23  
24 candidate neurochemical and imaging biomarkers of Alzheimer's disease. *Alzheimers Dement*  
25  
26 4, 38-48.  
27

28  
29 Hampel, H., Teipel, S.J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel,  
30  
31 R., Du, Y., Farlow, M., Moeller, H.J., Blennow, K., Buerger, K., 2004. Value of CSF beta-  
32  
33 amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive  
34  
35 impairment. *Mol Psychiatry* 9, 705-710.  
36

37  
38  
39 Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L., Blennow, K.,  
40  
41 2007. Prediction of Alzheimer's disease using the CSF A $\beta$ 42/A $\beta$ 40 ratio in patients with  
42  
43 mild cognitive impairment. *Dementia and geriatric cognitive disorders* 23, 316-320.  
44

45  
46 Herholz, K., 2003. PET studies in dementia. *Ann Nucl Med* 17, 79-89.  
47

48  
49 Herholz, K., Salmon, E., Perani, D., Baron, J.C., Holthoff, V., Froelich, L., Schoenknecht, P., Ito,  
50  
51 K., Mielke, R., Kalbe, E., Zundorf, G., Delbeuck, X., Pelati, O., Anchisi, D., Fazio, F.,  
52  
53 Kerrouche, N., Desgranges, B., Eustache, F., Beuthien-Baumann, B., Menzel, C., Schroeder,  
54  
55 J., Kato, T., Arahata, Y., Henze, M., Heiss, W.D., 2002. Discrimination between Alzheimer  
56  
57 dementia and controls by automated analysis of multicenter FDG PET. *Neuroimage* 17, 302-  
58  
59 316.  
60  
61  
62  
63  
64  
65

Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C.R., Jagust, W., Trojanowski, J.Q.,

Toga, A.W., Beckett, L., 2005. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). *Alzheimers Dement* 1, 55-66.

Petersen, R.S., Touchon, J., 2005. Consensus on mild cognitive impairment. *Res Pract Alzheimers Dis* 10, 24-32.

Tapiola, T., Pirttila, T., Mikkonen, M., Mehta, P.D., Alafuzoff, I., Koivisto, K., Soininen, H., 2000. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. *Neuroscience letters* 280, 119-122.

Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P., Buyse, M.A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., Vanmechelen, E., 2000. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. *Amyloid* 7, 245-258.

Zhong, Z., Ewers, M., Teipel, S., Buerger, K., Wallin, A., Blennow, K., He, P., McAllister, C., Hampel, H., Shen, Y., 2007. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. *Archives of general psychiatry* 64, 718-726.

**Table and figure legends**

Figure 1: Distribution of number of cases (healthy controls, MCI-, and AD-patients, total) in the centres

Table 1: Mean levels of measured neurochemical parameters within centres (pg/ml)

Table 2: Overall means  $\pm$  SD of different neurochemical parameters depending on diagnosis

Table 3: Ratios between fresh and frozen analytes (ratios are represented as means  $\pm$  SD)

Table 4: Correlations of the cumulative values of neurochemical parameters with and without freezing without consideration of centres

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Figure 1






Table 1

	Cerebrospinal Fluid						Plasma					
<i>Centre</i>	total tau-protein		phospho tau-protein 181		phospho tau-protein 231		beta-amyloid 42		beta-amyloid 40		beta-amyloid 42	
	Fresh	Frozen	Fresh	Frozen	Fresh	Frozen	Fresh	Frozen	Fresh	Frozen	Fresh	Frozen
Brescia	379±285	408±287	60±30	62±31	28±39	37±41	425±196	458±179	172±55	184±58	23±7	23±8
Copenhagen	394±275	398±236	61±27	60±23	22±40	26±45	538±250	636±370	169±41	198±44	26±8	26±7
Munich	413±311	430±304	63±16	51±15	-	18±21	626±256	503±184	150±43	186±48	20±10	24±9
Rome	243±134	274±150	40±18	40±19	11±19	13±21	439±157	367±152	172±42	174±49	17±5	20±6
Stockholm	377±64	440±45	63±5	63±6	32±13	44±12	400±74	441±91	174±93	187±87	16±4	18±6
Toulouse	-	-	-	-	-	-	-	-	152±41	172±16	20±6	22±9

Table 2

	<i>Parameter</i> <i>(pg/ml)</i>		Healthy Controls	MCI-subjects	AD-patients
CSF	total tau-protein	Fresh*	262±114	325±243	474±291
		Frozen	291±126	365±261	485±261
	phospho tau-protein 181	Fresh	50±15	59±28	60±23
		Frozen	48±15	56±29	58±21
	phospho tau-protein 231	Fresh	8±13	30±37	29±34
		Frozen	12±18	28±36	36±35
	CSF beta-amyloid 42	Fresh	588±193	457±256	440±145
		Frozen*	615±265	438±199	390±145
PLASMA	beta-amyloid 42	Fresh	23±8	21±6	18±8
		Frozen	24±7	23±7	20±8
	beta-amyloid 40	Fresh*	187±63	157±45	152±36
		Frozen*	208±52	178±49	166±42

\* Statistical significant differences between patients groups on post hoc analysis with Bonferroni LSD at  $p < 0.05$ .

Table 3

	Cerebrospinal Fluid			Plasma	
<i>Centre</i>	<i>phosphorylated tau-protein*</i>	<i>total tau-protein</i>	<i>beta-amyloid 42*</i>	<i>plasma beta-amyloid 40*</i>	<i>plasma beta-amyloid 42*</i>
Brescia	98±8	90±12	90±17	95±9	99±9
Copenhagen	100±6	100±23	90±18	85±5	98±14
Munich	124±9	95±9	125±9	81±13	83±13
Rome	103±17	91±17	125±39	104±40	84±10
Stockholm	100±3	86±10	92±17	91±7	92±6
Toulouse	-	-	-	87±17	92±8

\* Statistical significant differences between centres in Kruskal-Wallis ANOVA with on post hoc Bonferroni LSD test at  $p < 0.05$ .

Remarks:

*Phosphorylated tau-protein ratio:* Munich vs. Brescia, Copenhagen, Rome, and Stockholm ( $p=0.001$ ).

*CSF beta-amyloid 42 ratio:* Brescia vs. Munich ( $p=0.002$ ), vs. Rome ( $p=0.003$ ); Copenhagen vs. Munich ( $p=0.002$ ), vs. Rome ( $p=0.004$ ); Rome vs. Stockholm ( $p=0.014$ ); Stockholm vs. Munich ( $p=0.011$ ).

*Plasma beta-amyloid 40 ratio:* Munich vs. Rome ( $p=0.015$ ).

*Plasma beta-amyloid 42 ratio:* Brescia vs. Munich ( $p=0.002$ ), vs. Rome ( $p=0.004$ ); Copenhagen vs. Munich ( $p=0.006$ ), vs. Rome ( $p=0.011$ ).

Table 4

	<i>Marker (pg/ml)</i>	Fresh samples	Frozen samples	<i>r</i> value
CSF	total tau-protein	357±242	383±235	0.974 (p<0.0005)
	phosphorylated tau-protein 181	56±23	54±22	0.948 (p<0.0005)
	phosphorylated tau-protein 231	22±5	26±5	0.969 (p<0.0005)
	β-amyloid 42	498±209	484±228	0.855 (p<0.0005)
PLASMA	β-amyloid 42	20±8	22±8	0.936 (p<0.0005)
	β-amyloid 40	165±50	184±50	0.818 (p<0.0005)

Figure 1

